Pipeline forecasting can provide payers better insight into which expensive specialty drugs coming down the pipeline they should be keeping their eyes on, according to Katie Lockhart, MA, manager at Magellan Health.
Pipeline forecasting can provide payers better insight into which expensive specialty drugs coming down the pipeline they should be keeping their eyes on, according to Katie Lockhart, MA, manager at Magellan Health.
Transcript:
How is the growing specialty pipeline expected to impact payers financially?
Specialty is definitely the big topic in pharma right now within payers and everything, just simply because it's really cool on the one hand being able to treat diseases that we've never been able to treat before that had very limited treatment options, which is really great. Unfortunately, though, those things also come with a high cost due to the fact that there's a high cost in manufacturing and developing some of these things like the gene therapy drugs and CAR T [chimeric antigen receptor T-cell] therapies. So, because that has a high impact on payers, payers right now are especially interested in this. Because 1 drug that could release could have a significant impact on their budget and so they need to be prepared for that.
So, that's where forecasting has come in, and has been a big part and where we've seen a lot more questions around asking about what is the potential impact of this drug. Is this a blockbuster drug? Is this something that potentially I need to be prepared for? Because it could increase my spend significantly, whereas maybe in the past, that hasn't been as true. Now, with these newer treatment options and their high cost, that is becoming a higher concern.
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
Laundromats as a New Frontier in Community Health, Medicaid Outreach
May 29th 2025Lindsey Leininger, PhD, and Allister Chang, MPA, highlight the potential of laundromats as accessible, community-based settings to support Medicaid outreach, foster trust, and connect families with essential health and social services.
Listen
Zanubrutinib Shows Durable Benefit for High-Risk CLL/SLL at 5 Years in SEQUOIA Trial
June 6th 2025Zanubrutinib showed long-term efficacy in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and deletion of the 17p chromosome, with progression-free survival similar to patients without high-risk disease characteristics.
Read More
Real-World Data Support Luspatercept vs ESAs for Anemia in Lower-Risk MDS
June 5th 2025Patients with myelodysplastic syndrome (MDS) who received luspatercept showed greater hemoglobin gains and transfusion independence compared with erythropoiesis-stimulating agents (ESAs) in a real-world analysis.
Read More
At EHA 2025, Hematology Discussions Will Stretch Across Lifespans and Locations
June 5th 2025The 2025 European Hematology Association (EHA) Congress, convening virtually and in Milan, Italy, from June 12 to June 15, 2025, will feature a revamped program structure for the meeting’s 30th anniversary while maintaining ample opportunities to network, debate, and absorb practice-changing findings in hematology and oncology.
Read More